Physician profile
Robert Hernandez
NPI 1043247745
$5,718.44
in general payments reported to CMS, 2019-2025
39 companies · $94.51 in 2025
The $94.51 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $902 · 2020: $953 · 2021: $1,098 · 2022: $1,178 · 2023: $1,401 · 2024: $90.69 · 2025: $94.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,586.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,664.16 | 2019-2023 | Injectafer |
| Amgen INC. | $491.65 | 2019-2023 | Prolia, Evenity |
| Acadia Pharmaceuticals INC | $330.74 | 2019-2024 | Nuplazid |
| Abbvie INC. | $322.56 | 2021-2023 | |
| Novo Nordisk INC | $320.92 | 2019-2023 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $292.25 | 2019-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $267.53 | 2019-2023 | Farxiga |
| Pfizer INC. | $220.74 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $209.01 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $198.51 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $179.41 | 2019-2022 | |
| Glaxosmithkline, LLC. | $140.15 | 2020-2023 | Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $137.34 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $92.11 | 2024-2025 | Ingrezza |
| Kowa Pharmaceuticals America, INC. | $75.42 | 2020-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.